The US Court of Appeals for the Federal Circuit has affirmed a lower court ruling which said that a reissue patent covering Pfizer’s arthritis drug Celebrex was invalid for obviousness-type double patenting.
China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.
A US appeals court has for the second time invalidated a patent covering pharmaceutical company Teva’s multiple sclerosis drug Copaxone.
Law firm Pinsent Masons has expanded its Munich office with the hire of Marc Holtorf as partner.
US law firm Honigman Miller Schwartz and Cohn has hired two intellectual property lawyers as partners.
Recent patent decisions in the life sciences sector are leading biotechnology companies to seek protection for their innovations by using alternatives to patents, with trade secrets the most viable, the BIO International Convention has heard.
On day three of the BIO International Convention, LSIPR spoke to Kevin Noonan and Donald Zuhn, partners at law firm McDonnell Boehnen Hulbert & Berghoff and authors of the Patent Docs blog, about the possible impact of the Federal Circuit’s Ariosa v Sequenom decision on the life sciences industry.
Scott Kamholz, a former judge at the Patent Trial and Appeal Board, recently returned to law firm Foley Hoag as partner. LSIPR spoke to him at this year’s BIO International Convention, where he explained why the inter-partes review is not a “death squad” for patents.
Australia could be going down the road of no longer allowing gene patents, New Zealand-based patent lawyer David Nowak said at the BIO International Convention yesterday.
Philip Johnson, Johnson & Johnson’s senior vice president of intellectual property and policy, told the BIO International Convention yesterday that uncertainty around patent eligibility of inventions is a “silent killer of innovation”.